Compound of formula I ** Formula ** an enantiomer, a diasteromer or a pharmaceutically acceptable salt thereof in which J is N； W is CR2b； Z is -O- or -NR5-； Z * is -O-, -S (O) v-, or -NR5-； R2a is -H, R2b is -H or halo； Ra, Rb, Rc and Rd are each independently H, halo, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, cycloalkenyl, heterocycle, aryl, heteroaryl, -NO2, -CN, -NR5R5a, -OR4, -C (>； = O) R4, -C (>； = O) OR4； -C (>； = O) NR5R5a, -N (R5) C (>； = O) NR5R5a, -OC (>； = O) NR5R5a, -S (O) vR4, -S (O) 2NR5R5a, -N (R5) SO2R4 any of which may be optionally substituted independently with one or more R10 groups as permitted by valence； or Ra and Rb together with the carbon atom to which they are attached can be combined to form a 3-10 membered cycloalkyl, a 3-10 membered cycloalkenyl ring or a heterocycle ring, any of which may be optionally substituted with one or more R10 groups as allowed by valence； or Rc and Rd together with the carbon atom to which they are attached can be combined to form a 3-10 membered cycloalkyl, a 3-10 membered cycloalkenyl ring or a heterocycle ring, any of which may be optionally substituted with one or more R10 groups as allowed by valence； or Ra and / or Rb may be combined with any Rc or Rd to form a partially or fully saturated 3-8 membered heterocycle or cycloalkyl ring, any of which may be optionally substituted with one or more R10 groups as permitted by the Valencia； or Rc and Rd attached to the same carbon atom can be combined to form a carbonyl group； R1 is phenyl, naphthyl, isoquinolinyl, quinolinyl, naphthyridinyl, furopyridinyl, quinazoline, quinoxaline, any of which may be optionally substituted independently with one or more R10 groups as allowed in Valencia, R2 is phenyl, naphthyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl , tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, tetrahydropyridinyl, pyridinonyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, isoindolyl, indolinyl,
